Medication info
Hyundai Pregabalin Tablet 50 mg

Hyundai Pregabalin Tablet 50 mg

Prescription medicationTabletOral
Ingredient · strength
Pregabalin›50mg / 1 tablet
Manufacturer / importer
Hyundai Pharmaceutical Co., Ltd.
Appearance
White or light yellow round tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 201905352 · Approved 2019.07.29 · Insurance code 642004410

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy
Who takes it
Adults · Children
Adult dose
Administer the total daily dose of pregabalin in 2 divided doses orally, with or without food. Because this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg per day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation’.) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Although clinical studies were also conducted at a dose of 600 mg per day, there is no evidence of additional benefit or adequate tolerability at this dose. Doses exceeding 450 mg per day are not recommended, considering dose-dependent adverse reactions. 4. Discontinuation Based on current clinical experience, when discontinuing this medicine, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys as unchanged drug. Clearance of this medicine is directly affected by creatinine clearance; therefore, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an additional supplemental dose should be administered promptly after every 4 hours of hemodialysis. [Table 1]. Pregabalin dose based on renal function Creatinine clearance (CLcr), (mL/min) | Total daily dose of pregabalin a | Administration schedule | Starting dose (mg/day) | Maximum dose (mg/day) ≥60 | 150 | 600 | BID or TID ≥30 -<60 | 75 | 300 | BID or TID ≥15 -<30 | 25-50 | 150 | QD or BID <15 | 25 | 75 | QD Supplemental dose after hemodialysis | 25 | 100 | Single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified under the administration schedule. b: The supplemental dose refers to a dose administered as a single additional dose. 6. Patients with hepatic impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Elderly patients (aged 65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Ingredients

Manufacturer
Hyundai Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication helps relieve neuropathic pain in peripheral and central nerves in adult patients. Additionally, it is used as an adjunct in patients with epilepsy, particularly for those with partial seizures, assisting in symptom control. It is also effective in alleviating pain in patients with fibromyalgia. As such, it is widely used in the treatment of various neurological disorders.

How to take

Adult dose

Administer the total daily dose of pregabalin in 2 divided doses orally, with or without food. Because this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg per day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation’.) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Although clinical studies were also conducted at a dose of 600 mg per day, there is no evidence of additional benefit or adequate tolerability at this dose. Doses exceeding 450 mg per day are not recommended, considering dose-dependent adverse reactions. 4. Discontinuation Based on current clinical experience, when discontinuing this medicine, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys as unchanged drug. Clearance of this medicine is directly affected by creatinine clearance; therefore, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an additional supplemental dose should be administered promptly after every 4 hours of hemodialysis. [Table 1]. Pregabalin dose based on renal function Creatinine clearance (CLcr), (mL/min) | Total daily dose of pregabalin a | Administration schedule | Starting dose (mg/day) | Maximum dose (mg/day) ≥60 | 150 | 600 | BID or TID ≥30 -<60 | 75 | 300 | BID or TID ≥15 -<30 | 25-50 | 150 | QD or BID <15 | 25 | 75 | QD Supplemental dose after hemodialysis | 25 | 100 | Single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified under the administration schedule. b: The supplemental dose refers to a dose administered as a single additional dose. 6. Patients with hepatic impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Elderly patients (aged 65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Precautions

This drug may increase the risk of suicidal thoughts or behaviors, so if mood changes or abnormal behaviors occur during treatment, consult a physician immediately. Do not use if allergic to any of the ingredients in this medication. Patients with diabetes should be cautious as weight gain may necessitate adjustments in blood sugar control medications. If swelling occurs in the face or neck, stop taking this medication immediately and inform your healthcare provider. Elderly patients may experience increased dizziness or drowsiness while taking this medication, so special caution is advised during initial use. Blurred vision or changes in vision may occur, and if symptoms arise, consult a physician. Sudden discontinuation of this medication may result in withdrawal symptoms such as insomnia, headaches, and anxiety, so dosage adjustments should be discussed with healthcare providers. There is a risk of drug abuse, so if there is a history of substance misuse, consult a healthcare professional thoroughly before use. Patients with impaired kidney function may require adjustments to the dosage of this medication. Patients with heart disease should be cautious when taking this medication and inform their healthcare provider immediately if symptoms of heart failure occur. Concomitant use with other medications that have central nervous system depressant effects may increase the risk of respiratory depression, so follow healthcare provider instructions closely. Due to potential effects on the fetus, it is preferable for pregnant women not to take this medication; women of childbearing age should employ effective contraception. Breastfeeding women should consult healthcare professionals before use, as this medication can be transmitted through breast milk and may affect the baby. Be cautious when engaging in dangerous activities such as driving or operating machinery, as dizziness or drowsiness may occur due to this medication. In case of overdose, confusion, drowsiness, and depression may occur, and if necessary, blood dialysis or other treatments may be required. Children and elderly individuals should store this medication safely to prevent accidental ingestion.

Side effects

  • Suicidal thoughts
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • swelling around the mouth
  • upper respiratory tract swelling
  • dizziness
  • drowsiness
Show 206 more
  • loss of consciousness
  • confusion
  • mental disorder
  • visual disturbances
  • changes in vision
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • suicidal thoughts
  • pain
  • seizures
  • sweating
  • misuse
  • abuse
  • dependency
  • congestive heart failure
  • severe respiratory depression
  • rhinitis
  • neutropenia
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • depression
  • relief
  • decreased libido
  • insomnia
  • depersonalization
  • sexual sensation disorder
  • restlessness
  • nervousness
  • mood swings
  • emotional decline
  • emotional elevation
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • inability to suppress
  • apathy
  • dizziness
  • drowsiness
  • ataxia
  • motor coordination abnormalities
  • equilibrium disorders
  • amnesia
  • attention disorders
  • memory disorders
  • tremors
  • speech disorders
  • sensory abnormalities
  • sensory decrease
  • sedation
  • drowsiness
  • cognitive impairment
  • nystagmus
  • language disorders
  • myoclonus
  • decreased reflexes
  • movement disorders
  • psychomotor agitation
  • orthostatic dizziness
  • sensory hypersensitivity
  • burning sensation
  • activity tremor
  • syncope
  • confusion
  • decreased mobility
  • olfactory abnormalities
  • taste loss
  • writing difficulties
  • visual disturbances
  • diplopia
  • indirect vision loss
  • visual impairment
  • field loss
  • photophobia
  • dry eyes
  • eye swelling
  • decreased vision
  • eye pain
  • eye fatigue
  • increased tear secretion
  • eye irritation
  • mydriasis
  • vibration
  • depth perception changes in vision
  • strabismus
  • brightness in vision
  • vertigo
  • auditory hypersensitivity
  • first-degree heart block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • shortness of breath
  • nosebleed
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tightness
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distention
  • constipation
  • dry mouth
  • bloating
  • excessive salivation
  • gastroesophageal reflux disease
  • oral sensory decrease
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • maculopapular rash
  • urticaria
  • cold sweat
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasms
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urination disorders
  • urinary incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • breast pain
  • nipple discharge
  • breast enlargement
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • feeling intoxicated
  • altered sensations
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • loss of consciousness
  • mental disorder
  • keratitis
  • congestive heart failure
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • facial swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • drowsiness
  • confusion state
  • depression
  • agitation
  • restlessness
  • worsening of convulsions

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or humidity, so it should be stored in a tightly sealed container. Additionally, it is important to store the medication at room temperature between 1°C and 30°C to maintain its effectiveness.

Appearance and packaging

Appearance

White or light yellow round tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.